恒瑞医药：注射用SHR-9839(sc)获临床试验批准

南方财经网11-21

南财智讯11月21日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，同意开展临床试验。该药品为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，通过同时阻断与肿瘤发生发展相关的两条关键信号通路发挥抗肿瘤作用。此次获批将开展一项在实体瘤受试者中评价其安全性、耐受性及有效性的IB/II期研究。截至目前，SHR-9839相关项目...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2585119050?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-21 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585119050","market":"us","top_or_hot":-1,"title":"恒瑞医药：注射用SHR-9839(sc)获临床试验批准","media":"南方财经网","content":"<div>\n<p>南财智讯11月21日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，同意开展临床试验。该药品为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，通过同时阻断与肿瘤发生发展相关的两条关键信号通路发挥抗肿瘤作用。此次获批将开展一项在实体瘤受试者中评价其安全性、耐受性及有效性的IB/II期研究。截至目前，SHR-9839相关项目...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511213571522627.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药：注射用SHR-9839(sc)获临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药：注射用SHR-9839(sc)获临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-21 18:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202511213571522627.html><strong>南方财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>南财智讯11月21日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，同意开展临床试验。该药品为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，通过同时阻断与肿瘤发生发展相关的两条关键信号通路发挥抗肿瘤作用。此次获批将开展一项在实体瘤受试者中评价其安全性、耐受性及有效性的IB/II期研究。截至目前，SHR-9839相关项目...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202511213571522627.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1997245094.SGD","symbol_name":"安联神州A股基金AT Acc SGD","start_time":0,"source_url":"http://finance.eastmoney.com/a/202511213571522627.html","article_id":"2585119050","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585119050","pubTimestamp":1763719323,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"南财智讯11月21日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，同意开展临床试验。该药品为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，通过同时阻断与肿瘤发生发展相关的两条关键信号通路发挥抗肿瘤作用。此次获批将开展一项在实体瘤受试者中评价其安全性、耐受性及有效性的IB/II期研究。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0196":"行业龙头","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0239":"医药制造","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","01276":"恒瑞医药","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0183":"MSCI概念","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","BK0188":"融资融券","BK0012":"证金概念","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0028":"国家队","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK1191":"制药","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK0060":"抗癌","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC"},"translate_title":"Hengrui Medicine: SHR-9839 (sc) for injection was approved for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5},"content_text":"南财智讯11月21日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于注射用SHR-9839(sc)的《药物临床试验批准通知书》，同意开展临床试验。该药品为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，通过同时阻断与肿瘤发生发展相关的两条关键信号通路发挥抗肿瘤作用。此次获批将开展一项在实体瘤受试者中评价其安全性、耐受性及有效性的IB/II期研究。截至目前，SHR-9839相关项目累计研发投入约为7,231万元。 （文章来源：南方财经网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585119050","isCrawlerRequest":true}